Oocyte (Egg) Donation — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Oocyte (egg) donation is an assisted reproductive technology (ART) process in which eggs (oocytes) are retrieved from a healthy egg donor following controlled ovarian stimulation and used to create embryos via in vitro fertilisation (IVF) for transfer to a recipient who is unable to use her own eggs. The procedure separates the genetic contribution (from the donor) and gestational contribution (from the recipient) in reproduction. The donor undergoes a hormonal stimulation protocol (typically 10–14 days of recombinant FSH injections with or without LH, titrated by transvaginal ultrasound monitoring) to produce multiple follicles, followed by transvaginal oocyte retrieval under ultrasound guidance under conscious sedation or short general anaesthesia. Retrieved eggs are immediately fertilised in the laboratory with partner or donor sperm by conventional IVF (oocyte and sperm co-incubation) or ICSI (intracytoplasmic sperm injection — directly injecting a single sperm). The resulting embryos are cultured for 3–5 days to blastocyst stage, graded, and either transferred fresh to a synchronised recipient uterus or vitrified (flash-frozen) for future frozen embryo transfer (FET). Egg donation is regulated by national fertility laws — in many countries, altruistic anonymous donation is permitted; in others, known or identified donation is required.

Egg donation is indicated for women who cannot achieve pregnancy using their own eggs due to egg quantity or quality problems. The primary medical indications include premature ovarian insufficiency (POI, formerly premature ovarian failure) — where the ovaries stop functioning before age 40 — causing a loss of eggs and ovarian hormonal function; menopause (natural, surgical, or iatrogenic from chemotherapy/radiotherapy); diminished ovarian reserve (DOR) with poor response to stimulation (fewer than 3–4 follicles on maximum stimulation, AMH below 1 pmol/L, AFC below 3), where own-egg IVF failure rates exceed 80–90%; repeated IVF failure with poor egg quality or recurrent embryo arrest; genetic diseases with autosomal dominant or X-linked inheritance patterns where the female partner is a carrier or affected; and advanced reproductive age (women over 42–45 years where own-egg live birth rates per transfer are below 5%). Male same-sex couples and single men using gestational surrogacy require egg donation. Recipient suitability assessment includes uterine evaluation (hysteroscopy, saline sonogram), hormonal preparation capacity, cardiovascular and general health assessment, and psychological counselling — pregnancy via egg donation after age 50 is controversial and associated with elevated obstetric risks.

The donor and recipient cycles are coordinated by the fertility clinic. The donor undergoes a medical screening assessment (AMH, AFC, karyotype, infectious disease screening, genetic carrier screening, psychological evaluation) before acceptance. Stimulation begins on day 2–3 of the donor's menstrual cycle with daily subcutaneous gonadotropin injections (recombinant FSH 150–300 IU/day), monitored by transvaginal ultrasound and serum oestradiol levels every 2–3 days. A GnRH antagonist is added from day 5–6 to prevent premature ovulation. When the lead follicles reach 17–18 mm diameter and oestradiol levels are appropriate, a final trigger injection (hCG or GnRH agonist) is given and oocyte retrieval scheduled 34–36 hours later. Transvaginal ultrasound-guided oocyte retrieval is performed under conscious sedation: a needle is passed transvaginally into each follicle under ultrasound guidance, aspirating follicular fluid containing the cumulus-oocyte complexes. The embryologist identifies and grades retrieved oocytes (mature MII stage = suitable for fertilisation). The retrieved oocytes are fertilised by ICSI within 2–4 hours. The recipient's uterus is simultaneously prepared with oestrogen supplementation (oral, transdermal, or vaginal) starting 2–3 weeks before, timed to achieve an endometrial thickness of at least 7–8 mm. Progesterone is added 5 days before embryo transfer to synchronise with embryo development. One or two blastocysts are transferred transcervically to the recipient's uterus using a soft catheter under ultrasound guidance. Luteal support (progesterone) continues for 10–12 weeks if pregnancy is confirmed.

Egg donation consistently achieves the highest live birth rates of any IVF treatment modality, as the recipient's age has limited impact on success when high-quality donor eggs are used. Per embryo transfer live birth rates with donor eggs are 40–55% in most experienced programmes — significantly higher than own-egg IVF in women over 40 (less than 5–15%). Cumulative live birth rates from a complete egg donation cycle (multiple transfers from one retrieval) reach 70–80% in many programmes. The consistency of outcomes reflects the dominant role of egg quality (determined by the young donor's age, typically 18–34 years) over endometrial receptivity in determining IVF success. Frozen embryo transfer (FET) with vitrified donor embryos achieves equivalent or superior outcomes to fresh transfer in most studies, and offers flexible scheduling without cycle synchronisation constraints. For recipients with premature ovarian insufficiency, egg donation is the only effective treatment option. ESHRE data from Europe demonstrate consistent live birth rates of 45–55% per oocyte donation cycle across European clinics, with pregnancy loss rates no higher than spontaneous conception in the same age group.

Risks are distinct for donors and recipients. Donor risks from ovarian stimulation include ovarian hyperstimulation syndrome (OHSS) — the most serious acute complication, characterised by enlarged ovaries, ascites, haemoconcentration, and electrolyte disturbances. Moderate-to-severe OHSS affects 1–2% of stimulated donors; GnRH agonist triggering (instead of hCG) virtually eliminates this risk in fresh donor cycles. Other donor risks include discomfort from follicular monitoring injections, transient bloating and pelvic discomfort from multi-follicular ovarian enlargement, transvaginal retrieval-related bleeding (less than 1%), infection (pelvic inflammatory disease, less than 0.5%), and injury to adjacent structures (bladder, bowel, vessels) — all rare. Long-term risks of multiple egg donation cycles on donor fertility remain uncertain; most regulatory authorities limit the number of donation cycles. Recipient risks include multiple pregnancy (when two embryos are transferred — now mitigated by single embryo transfer policies), miscarriage (15–25%, similar to natural conception at matched donor age), ectopic pregnancy (2%), placenta praevia and preterm birth at slightly higher rates than spontaneous conception in some studies, and hypertensive disorders of pregnancy at higher rates in oocyte donation pregnancies compared with own-egg IVF.

Egg retrieval is a day-case procedure. The donor is observed for 1–2 hours post-procedure and discharged once fully recovered from sedation. Mild pelvic cramping, bloating, and spotting are normal for 2–5 days after retrieval. Rest for 24 hours is advised; light activities resume the next day; strenuous exercise and intercourse are avoided for 7 days. Menstruation occurs 10–14 days after retrieval. Donors are monitored by the clinic for symptoms of OHSS for the first week. The recipient's embryo transfer procedure is a simple outpatient procedure taking 15–20 minutes — no anaesthetic or special preparation is required. The recipient remains on progesterone supplementation for 10–12 weeks if pregnancy test is positive. A serum beta-hCG is performed 10–14 days after transfer. If positive, the first early pregnancy ultrasound is at 6–7 weeks. Ongoing pregnancy is managed by the obstetric team, who should be informed of the egg donation history. Psychological support before, during, and after treatment — for donors, recipients, and regarding disclosure to future children — is an essential component of comprehensive egg donation care in ethical programmes.